Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 14/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325234 | 1.00 | TSHR (0.59) | TSHRGPR84MPOHTR2ATRPM8 | |
| SCHEMBL3567795 | 0.81 | MEN1 (0.51) | TSHRGPR84MPOHTR2AKMT2A | |
| SCHEMBL13316003 | 0.81 | MEN1 (0.51) | TSHRGPR84MPOHTR2AKMT2A | |
| SCHEMBL3567792 | 0.81 | MEN1 (0.51) | TSHRGPR84MPOHTR2AKMT2A | |
| SCHEMBL2260803 | 0.75 | TSHR (1.00) | TSHRGPR84MPOHTR2ATRPM8 | |
| SCHEMBL14663385 | 0.74 | GPR84 (0.69) | TSHRGPR84MPOHTR2ATRPM8 | |
| SCHEMBL1722756 | 0.74 | GPR84 (0.73) | TSHRGPR84MPOHTR2ATRPM8 | |
| SCHEMBL20388709 | 0.74 | TSHR (0.75) | TSHRGPR84MPOHTR2ATRPM8 | |
| Hydrochloric Acid SCHEMBL1372337 | 0.74 | TSHR (0.97) | TSHRGPR84MPOHTR2ATRPM8 | |
| SCHEMBL2177075 | 0.74 | TSHR (0.75) | TSHRGPR84MPOHTR2ATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2722333-A1 | Spiro-indole derivatives for the treatment of parasitic diseases. | Novartis AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| EP-2285808-B1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8399453-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-03-19 | — | — | US | disclosed |
| US-20110275613-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-10 | — | — | US | disclosed |
| US-8053442-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275560-A1 | ORGANIC COMPOUNDS | OTC, PC, OAT | TSHR 4271/4885GPR84 3128/4885MPO 97/4885 |
| US-20110275613-A1 | ORGANIC COMPOUNDS | OTC, PC, OAT | TSHR 4260/4885GPR84 3092/4885MPO 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.